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Leukotrienes (LTs) are potent biological proinﬂammatory mediators. LTC4, LTD4, and LTE4 are more frequently involved in
chronicinﬂammatoryresponsesandexerttheiractionsbindingtoacysteinyl-LT1(CysLT1)receptorandacysteinyl-LT2(CysLT2)
receptor. LTs receptor antagonists available for clinical use demonstrate high-aﬃnity binding to the CysLT1 receptor. In this
paper the employment of anti-LTs in allergic cutaneous diseases is analyzed showing that several studies have recently reported
ab e n e ﬁ c i a le ﬀects of these agents (montelukast and zaﬁrlukast as well as zileuton) for the treatment of some allergic cutaneous
related diseases-like chronic urticaria and atopic eczema although their proper application remains to be established.
1.Introduction
Several studies have recently reported a beneﬁcial eﬀects
of leukotriene (LT) receptor antagonists (montelukast and
zaﬁrlukast) as well as zileuton, a 5-lipoxygenase inhibitor, for
the treatmentof some allergic cutaneous related diseases-like
chronic urticaria and atopic eczema [1, 2], although their
proper application remains to be established [2].
Although histamine is considered the principal media-
tor of immediate allergic responses, other factors (kinins,
prostaglandins and LTs) prolong the inﬂammatory process
in the so-called late phase response of allergic reaction [1]
thus causing the poorly responsiveness of symptoms to the
treatment with antihistamine agents only [3].
Leukotrienes (LTs) are a class of potent biological pro-
inﬂammatory mediators derived from arachidonic acid
through the 5-lipoxygenase pathway divided into two groups
according to their chemical structure: those with a sulphur
linkage or cysteinyl LTs: LTC4, LTD4, LTE4 are more
frequently involved in chronic inﬂammatory responses and
exert their actions through the binding to two types of
activating receptors: a cysteinyl-LT 1 (CysLT1) receptor and
a cysteinyl-LT 2 (CysLT2) receptor [4, 5].
Eosinophils,basophilsandmastcellsarethemostimpor-
tant sources of cysteinyl-LTs and epidermal cells are able to
transform neutrophil-derived LTA4 into LTB4 and LTC4 [6].
Thus the epidermis can also contribute signiﬁcantly to LT
synthesis in situ.
Surely Cys-LTs play a role in promoting and maintaining
the allergic inﬂammatory response in cutaneous disease as
atopic dermatitis and chronic urticaria as well as in asthma
through their active eﬀects on chemotaxis, vasodilatation
and oedema, LTs are, in fact, potent spasmogenic and
chemotactic agents that increase capillary and small vessels
permeability. When LTs are injected into human skin, they
cause wheal and ﬂare reactions [7], with an action 100-fold
more potent than histamine, and consequent sensory nerve
stimulation that provokes itching and pain [8, 9].2 Mediators of Inﬂammation





















of Leukotrienes -E4 [12]
There is evidence of enhanced LT production in the
pathogenesis of AD. Patients with AD have activated cir-
culating basophils and increased basophil and neutrophil
releasability of LT-C4 compared with healthy subjects [10,
11], while urinary levels of LT-E4, a stable metabolite of
LT-C4 and LT-D4, has been showed high levels in children
aﬀected by severe atopic eczema, but not in healthy normal
subjects or in patients with mild or moderate atopic eczema
[12] .T h er o l eo fL e u k o t r i e n e si na l l e r g o l o g i c a lc u t a n e o u s
diseases is shown in Table 1.
Actually, three LTs receptor antagonists are available for
clinical use, montelukast, used in patients older than 6 years,
and zaﬁrlukast, approved for adolescent and adult subjects.
Montelukast, Zaﬁrlukast and Pranlukast [13] are LT receptor
antagonists that demonstrate high-aﬃnity binding to the
CysLT1 receptor.
2. Leukotriene Receptor Antagonistsin
ChronicUrticaria
The EEACI/GA2LEN/EDF guideline for the management of
urticaria is a consensus reached during panel discussion at
the Second International Consensus Meeting on Urticaria,
Urticaria 2004 [14], joint initiative of the EAACI Derma-
tology Section and GA2LEN and they have been updated
recently [15]. According to this guideline, management is
divided into three basic approaches.
First approach is avoidance, elimination or treatment
of eliciting stimulus or cause. This is the best way since
identiﬁcation of the cause allows successful treatment;
however, it may not be possible in all cases. It includes
elimination of medicaments, physical stimuli, eradication of
infectious agents and treatment of inﬂammatory processes,
and also removal of autoantibodies to the high-aﬃnity IgE
receptor. It is applicable in patients with IgE-mediated or
physical urticaria. Second approach is inhibition of mast
cell mediator release and nowadays the most commonly
used drugs inhibiting mast cell release are corticosteroids.
Other drugs with inhibiting activity on mast cells are, for
example cyclosporin A and PUVA therapy. In the light of
these considerations, even the LTs receptor antagonists could
play a their role in the treatment of chronic urticaria [1, 16].
The chronic urticaria shows diﬀerent complex aspects
in its pathogenesis: approximately 45% of patients with
chronic urticaria have an IgG autoantibody directed to the
alphasubunit of the high-aﬃnity IgE receptor leading to
cutaneous mast cell and basophil activation [17], but it has
been recently evidenced that the coagulation cascade and
ﬁbrinolysis activation could be involved in the pathomech-
anism of chronic urticaria [18], whom contribute to form
serum histamine releasing antibodies.
At last the third approach to urticaria is based on therapy
to target organ, for example, antihistamines, according to
EEACI/GA2LEN/EDF guideline [15], but chronic urticaria
is often diﬃcult to treat and may not be controlled with
the conventional antihistamine therapy alone [19], despite
the new generation antihistamines such as cetirizine, levoce-
tirizine, loratadine, desloratadine and fexofenadine provide
both antiallergic and antiinﬂammatory eﬀects such as inhi-
bition of cytokines release from basophiles and mast cells as
well as reduction of chemotactic activity of eosinophils [20]
Based on the important role of LTs in the patho-
physiologic mechanisms of allergic inﬂammation, antiLT
receptors, montelukast and zaﬁrlukast, have recently been
used, either as monotherapy or in combination with H1-
receptorantagonists,totreatdiﬀerentformsofurticaria[21].
The results of several studies have indicated a positive
therapeutic eﬀect of antiLTs in such diﬀerent conditions
as chronic urticaria, (especially the severe urticaria-
angioedema induced by acetylsalicylic acid (ASA) and
by other nonsteroidal antiinﬂammatory drugs), cold
urticaria, urticaria related to food additives, chronic
autoimmune urticaria, steroid-dependent urticaria, delayed-
pressure urticaria, chronic idiopathic urticaria and, ﬁnally,
dermographism [13, 22–25].
A single study reported that pranlukast may provoke
urticaria in patients with ASA-induced urticaria; however,
t h i sm o l e c u l ei sn o ta v a i l a b l ei nE u r o p e[ 26].
A better therapeutic eﬀect of montelukast versus ceti-
rizine or placebo has been demonstrated by Pacor et al. in
a double-blind, placebo-controlled trial in patients suﬀering
from chronic urticaria related to food additive and/or ASA
intolerance [27]. The same authors also studied 160 patients
aﬄicted by moderate chronic idiopathic urticaria. In this
study, patients were divided into four harms: the ﬁrst harm
received montelukast alone, the second harm was treated
with montelukast plus desloratadine, patients in the third
harm were treated with desloratadine and, ﬁnally, the fourth
harmreceiveddesloratadinewithplacebo.Thisstudyshowed
that the therapeutic regimen based on the association of
monteleukast and desloratadine was eﬀective in controlling
symptoms of urticaria, even though the second drug proved
more eﬃcacious than the LTs antagonist [28]. In light of
their observations, the authors supported the eﬃcacy of a
combination of antiLTs and nonsedating antihistamine for
the treatment of urticaria elicited by a well known factor,
such as ASA or food additives-induced urtricaria, autoim-
mune urticaria, acquired cold urticaria and delayed pressure
urticaria. While the association of LT receptor antagonists
and H1-antihistamine drugs in patients suﬀering from
idiopathic urticaria, according to the same AA., would not
add any beneﬁcial eﬀect, compared with the antihistamine
monotherapy [28]. Bagenstose and colleagen. obtained simi-
lar results: they observed a beneﬁcial eﬀe c tf r o mac o m b i n e d
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aﬀected by severe autoimmune urticaria, showing a positive
skin response to autologous serum test [29].
According to Nettis et al. positive and better results in
terms of improvement of symptoms were obtained with
a treatment based on montelukast alone, compared with
fexofenadine in patients suﬀering from chronic idiopathic
urticaria; in the same patients these AA. also demonstrated
a reduction of wheal performing the autologous serum test
after montelukast treatment [30].
In another randomized, double-blind, placebo-con-
trolled study on patients with mild chronic urticaria, Nettis
also demonstrated that the concomitant administration
of desloratadine and montelukast provides a signiﬁcant
improvement in overall urticaria conditions, compared
with placebo and desloratadine alone [31]. Eﬀectiveness of
therapy with antiLTs in the treatment of chronic idiopathic
urticaria has also been demonstrated by Erbagci [32].
He conducted a single-blind, placebo-controlled, cross-over
clinical study with montelukast versus placebo, using nonse-
dating antihistamine when needed. In this study, he showed
that montelukast is an eﬀective and safe therapeutic agent in
the treatment of refractory chronic idiopathic urticaria [32].
Norris and Sullivan, studying LTs and cytokines in
steroid-dependent urticaria, found that 60% of patients
enrolled in the study manifested a signiﬁcant improvement
of their severe symptoms taking zaﬁrlukast in combination
with antihistamines [33].
Sanada et al. conﬁrmed the eﬀectiveness of montelukast
in chronic urticaria unresponsive to the antihistamine
treatment and, at variance from other observations, they
did not reported diﬀerences between patients with positive
skin reactions to autologous sera and/or those with ASA
hypersensitivity. While critical factors were represented by
age and duration of symptoms, whereby young patients
having a illness for short duration, were more responsive to
the treatment with montelukast [34].
Aseroshowedanearlytotalremissionofthediseaseinthe
half of twelve patients with unremitting, steroid-dependent
urticaria, after treatment with montelukast 10mg once a
day or zaﬁrlukast 20mg twice a day. Therefore, according to
Asero and on the basis of the safety, tolerability and low cost,
LTreceptorantagonistsshouldbeadministeredinallpatients
with steroid-dependent chronic urticaria, unresponsive to
other therapies [35].
Reimers et al. by realizing a double-blind, placebo-
controlled, cross-over study with 20mg daily of zaﬁrlukast,
demonstrated the ineﬀectiveness of antiLTs in the treatment
of chronic urticaria, concluding that LTs have no signiﬁcant
role in the aetiology of this disease. However, evaluating
their results, it is important to consider that they observed
in 19 cases (41.3%) a resolution of chronic urticaria that
was interpreted as a spontaneous remission, on the basis
of the high variability of the course of chronic urticaria
[36].
Regarding to this aspect, Nettis et al. observed that
the remission or improvement of the urticaria induced by
antiLTs therapy could not be considered as a spontaneous
remission because the excellent results were recorded after
3 weeks of active treatment [30]. Further, Nettis and coll.
demonstrated the eﬀectiveness, high tolerability and safety
of montelukast also in delayed pressure urticaria [37]. In
particular, comparing loratadine plus montelukast versus
loratadine monotherapy, administered for two weeks, the
authors reported a more marked improvement of this form
of urticaria in patients treated with montelukast combined
with loratadine than loratadine alone. They described a
negative result of the rechallenge test in 80% of patients
enrolled to the combined therapy versus 20% of subjects that
received loratadine monotherapy [37]. In another group of
delayed pressure urticaria patients, the same authors tested
the treatment with desloratadine in association with mon-
telukast versus desloratadine alone, reporting encouraging
results. In fact, they observed that both, desloratadine alone
and desloratadine plus montelukast, improved urticaria in
respecttothebaselineassessment.However,thecombination
of antihistamine with antiLTs resulted more eﬃcacious in
the suppression of symptoms and the wheal with dermo-
graphometer challenge test [38].
A successful treatment of delayed pressure urticaria with
montelukast has been reported also by Berkun and Shalit
[39]. He described a case of a patient with severe steroid-
dependent delayed pressure urticaria, not-responding to
several diﬀerent antihistamines and other therapies. In this
patient, the administration of 10mg daily of montelukast
induced the remission of clinical manifestations after one
week of treatment [39].
Finally, since Asero has suggested a common link among
chronic urticaria, NSAIDs cutaneous hypersensitivity and
alterations of coagulative cascade [40, 41] some single cases
have been reported by diﬀerent authors investigating the
promising use of LT receptors inhibitors as prevention care
of severe urticaria/angioedema exacerbations following
NSAIDs assumption in patients with chronic urticaria [42–
44], even if neither clinical nor observational study enrolling
large groups of these patients has been ever performed as
well as in NSAIDs intolerant asthmatics [45]. Curiously, it
has been showed low doses of pranlukast seem to induce
urticarial eruption in aspirin sensitive patients as paradox
eﬀect [26].
3. Leukotriene Receptor Antagonistand
Atopic Eczema
LTs are also involved in the pathogenesis of other atopic skin
disorders. In particular, atopic dermatitis or Atopic Eczema
Dermatitis Syndrome (AEDS), similarly to the diﬀerent
forms of urticaria, are associated with inﬁltration and
activation of mast cells and consequent release of vasoactive
and pro-inﬂammatory mediators at the cutaneous level.
This mechanism is indirectly supported by the results of
some studies which revealed the eﬀectiveness of LTs receptor
antagonists in the treatment of AEDS. In this connection,
Nettis and colleagues showed, in a placebo-controlled study,
that a 6-week treatment with montelukast was eﬀective in
inducing a moderate reduction of cutaneous inﬂammation,
as evaluated by the SCORAD index, in 20 adults suﬀering
from moderate to severe AEDS [46].4 Mediators of Inﬂammation
Positive eﬀects of therapy with antiLTs in AEDS have
also been reported by other authors. Yanase and David-
Bajar showed a statistically signiﬁcant improvement of the
clinical manifestations of atopic dermatitis of moderate
severity in adult patients receiving 10mg of montelukast
for 8 weeks [47]. In the study of Pei and colleagen, young
AEDS patients were treated with montelukast 5mg, once a
day for 4 weeks. At the end of the study, patients receiving
the drug had a beneﬁcial eﬀect, compared to the placebo-
treated group [48]. Similarly, Carucci et al. reported eﬃcacy
of zaﬁrlukast treatment in the same disease [49]. Angelova-
Fisher and Tsankov demonstrated that montelukast, used as
singletherapeuticagent,wascapabletoimprovesigniﬁcantly
the clinical manifestations of severe AEDS. In particular,
they described a reduction of erythema and exudation after
10 days of treatment with montelukast monotherapy and
an improvement of pruritus just within the ﬁrst week of
treatment, in two AEDS patients [50].
By contrast, some other interventional studies in atopic
eczema were not able to show any superiority of treatments
basedonLTsantagonistinrespecttoothertreatmentoptions
or placebo. In particular, Capello et al. compared two treat-
mentregimensbasedon(a)10mgonceadayofmontelukast
and (b) a combined regimen (orally administered cetirizine
and clarythromycin, topical corticosteroids and hydrating
preparations), in 32 adult patients with moderate-to-severe
atopic dermatitis; no diﬀerence in the reduction of the
SCORAD index in the two treatment groups was reported
[51]. Moreover, Friedmann et al. conducted a random-
ized, double-blind, placebo-controlled trial which did not
demonstrate any eﬃcacy of montelukast over placebo in the
treatment of moderately severe adult atopic eczema [52].
These ﬁndings were also conﬁrmed by Silverberg and Paller
that reported a lack of eﬃcacy administering montelukast
or zaﬁrlukast in seven patients with atopic dermatitis.
Speciﬁcally, the treatment determined only a temporary
symptomatic relief [53]. Therefore, in the authors’ opinion
antiLTs were unable to provide a permanent beneﬁt in
patients suﬀering from diﬀuse atopic dermatitis [53].
4. Conclusion
In conclusion, experimental data suggest that LTs are
involved in the allergic inﬂammation, even though their
precise pathogenetic role has not been elucidated [9]. These
ﬁndings induced several authors to test LTs antagonists in
the treatment of chronic urticaria and atopic dermatitis
in patients poorly responsive to the conventional therapy.
Actually, the available results on the eﬃcacy of antiLTs are
encouraging but contrasting and not uniform. Beneﬁts have
been reported with antiLTs drugs in some forms of urticaria
and atopic dermatitis, although to a diﬀerent extent, by
the several studies. Prospective studies aimed at detecting
patients that would beneﬁt from antiLTs drugs are warranted
[35]. However, on account of the good tolerability and
safety of antiLTs agents, also in long-term therapy [37], a
treatment with these drugs should be tried in all cases of
urticaria or atopic eczema unresponsive to the conventional
therapy.
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